We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Prof
Study
team
canpdp.trialoffice@kcl.ac.uk
Dr
Sagnik
Bhattacharyya
sagnik.2.bhattacharyya@kcl.ac.uk
Dr
Latha
Velayudhan
latha.velayudhan@kcl.ac.uk
Extrapyramidal and movement disorders
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Parkinson's disease psychosis is a symptom of Parkinson's disease that causes patients to experience hallucinations and/or delusions. More than half of all patients with Parkinson's disease eventually develop these symptoms over the course of their disease. These problems can be difficult to manage and can impact quality of life. Currently, existing medications to treat these symptoms are either not very effective or have significant side effects.
In the main clinical trial , Cannabidiol for Parkinson’s Disease Psychosis (CAN-PDP), we aim to test an investigational medicine called cannabidiol (CBD). The purpose of this trial is to look at how safe and well CBD works in patients with Parkinson’s disease psychosis, and how well it is tolerated.
Another important aspect of the CAN-PDP trial will be to investigate the effect of CBD on the brain function of Parkinson’s patients with psychosis. To do this, we would like to compare the brains of people from the CAN-PDP trial to the brains of people with Parkinson’s, but without psychosis, and healthy volunteers without Parkinson’s using magnetic resonance imaging (MRI). Hence this mechanistic MRI control study.
In order to do this we will include:
1.20 participants with Parkinson’s disease (without psychosis)
2.20 healthy controls
Both groups will undergo the following study-related procedures:
•Screening visit where will assess eligibility and collect baseline demographic and clinical data
•Questionnaires to assess for Parkinson’s disease, cognitive impairment and psychotic symptoms
•MRI scanning session that will last approximately 60 minutes at King’s College London, Denmark Hill
Neuroimaging data will be acquired using well-established protocols (both task-based and resting fMRI and structural MRI) on the 3T MRI scanner at the NIHR King's Wellcome Clinical Research Facility or Centre for Neuroimaging Sciences, Denmark Hill.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Case-controlled study;
You can take part if:
You may not be able to take part if:
PD participants 1. PD patients who ever experienced formed hallucinations or delusions during their course of PD illness 2. History of significant psychotic disorders prior to or concomitantly with the diagnosis of Parkinson’s disease including, but not limited to, schizophrenia or bipolar disorder. 3. Pregnant or breastfeeding 4. Has any metal implant or objects, such as: pacemakers, medication pumps, aneurysm clips, metallic prosthesis (such as heart valves or cochlear implants), certain orthopaedic implants (pins and rods); any metallic fragment or foreign body, such as: shrapnel, or small metal fragments in the eye; has claustrophobia. 5. Concurrent participation in any CTIMP with novel pharmacological intervention. Healthy controls 1. Pregnant or breastfeeding 2. Significant psychiatric or neurological disorder 4. Has any metal implant or objects, such as: pacemakers, medication pumps, aneurysm clips, metallic prosthesis (such as heart valves or cochlear implants), certain orthopaedic implants (pins and rods); any metallic fragment or foreign body, such as: shrapnel, or small metal fragments in the eye; has claustrophobia. 5. Concurrent participation in any CTIMP with novel pharmacological intervention.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Sagnik
Bhattacharyya
sagnik.2.bhattacharyya@kcl.ac.uk
Prof
Study
team
canpdp.trialoffice@kcl.ac.uk
Dr
Latha
Velayudhan
latha.velayudhan@kcl.ac.uk
The study is sponsored by King's College London and funded by PARKINSON'S DISEASE SOCIETY OF THE UNITED KINGDOM .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 48337
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
